EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

COVID-19: Not a thrombotic disease but a thromboinflammatory disease

Shu He, Margareta Blombäck, Håkan Wallén

Upsala Journal of Medical Sciences · 2024

DOI: 10.48101/ujms.v129.9863 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Upsala Journal of Medical Sciences, 2024. Verfasst von Shu He und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: COVID-19, Thrombosis, Blood Coagulation Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While Coronavirus Disease in 2019 (COVID-19) may no longer be classified as a global public health emergency, it still poses a significant risk at least due to its association with thrombotic events. This study aims to reaffirm our previous hypothesis that COVID-19 is fundamentally a thrombotic disease. To accomplish this, we have undertaken an extensive literature review focused on assessing the comprehensive impact of COVID-19 on the entire hemostatic system. Our analysis revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly enhances the initiation of thrombin generation. However, it is noteworthy that the thrombin generation may be modulated by specific anticoagulants present in patients’ plasma. Consequently, higher levels of fibrinogen appear to play a more pivotal role in promoting coagulation in COVID-19, as opposed to thrombin generation. Furthermore, the viral infection can stimulate platelet activation either through widespread dissemination from the lungs to other organs or localized effects on platelets themselves. An imbalance between Von Willebrand Factor (VWF) and ADAMTS-13 also contributes to an exaggerated platelet response in this disease, in addition to elevated D-dimer levels, coupled with a significant increase in fibrin viscoelasticity. This paradoxical phenotype has been identified as ‘fibrinolysis shutdown’. To clarify the pathogenesis underlying these hemostatic disorders in COVID-19, we also examined published data, tracing the reaction process of relevant proteins and cells, from ACE2-dependent viral invasion, through induced tissue inflammation, endothelial injury, and innate immune responses, to occurrence of thrombotic events. We therefrom understand that COVID-19 should no longer be viewed as a thrombotic disease solely based on abnormalities in fibrin clot formation and proteolysis. Instead, it should be regarded as a thromboinflammatory disorder, incorporating both classical elements of cellular inflammation and their intricate interactions with the specific coagulopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ThrombosisBlood Coagulation DisordersHumansSARS-CoV-2ThrombinInflammationFibrin

Stichwörter der Autor:innen

COVID-19endothelia damagefibrinolysis shutdownhyper-coagulationplatelet activation

Substanzen

ThrombinFibrin

Autor:innen und Institutionen

  • Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Division of Coagulation Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Zitieren

APA

He, S., Blombäck, M., & Wallén, H. (2024). COVID-19: Not a thrombotic disease but a thromboinflammatory disease. Upsala Journal of Medical Sciences. https://doi.org/10.48101/ujms.v129.9863

Vancouver

He S, Blombäck M, Wallén H. COVID-19: Not a thrombotic disease but a thromboinflammatory disease. Upsala Journal of Medical Sciences. 2024. doi:10.48101/ujms.v129.9863

BibTeX
@article{He2024,
  author = {He, Shu and Blombäck, Margareta and Wallén, Håkan},
  title = {COVID-19: Not a thrombotic disease but a thromboinflammatory disease},
  journal = {Upsala Journal of Medical Sciences},
  year = {2024},
  doi = {10.48101/ujms.v129.9863}
}
Kostenlos starten →